What’s Schrodinger Inc (SDGR) Working Out with Anthropic?

Why It Matters

The shift to hosted contracts and AI‑enhanced tools positions Schrödinger to capture higher‑margin recurring revenue and accelerate biotech customers’ drug‑development cycles, a critical advantage in a competitive AI‑driven pharma software market.

Key Takeaways

• Target: 75% of contracts hosted by 2029.
• AI integration with Anthropic to boost platform efficiency.
• Q4 2025 revenue $87.2M, beating estimates.
• Drug discovery revenue doubled YoY to $18M.
• Eli Lilly partnership adds TuneLab to LiveDesign cloud.

Pulse Analysis

Schrödinger Inc. (SDGR) is accelerating its transition from traditional on‑premise licensing to a cloud‑first, hosted software model, a move that mirrors broader trends in the life‑science technology sector. By targeting 75% of contracts to be hosted within three years, the company aims to lock in recurring subscription revenue, improve scalability, and meet biotech firms’ demand for flexible, on‑demand compute resources. The integration of generative‑AI from partners like Anthropic promises to streamline molecular simulations and design workflows, potentially cutting weeks off drug‑candidate identification.

Financially, Schrödinger delivered $87.2 million in Q4 2025 revenue, modestly below the prior year but comfortably above analyst forecasts. The modest decline reflects a strategic shift in revenue recognition as the firm moves toward hosted contracts, while drug‑discovery revenue surged to $18 million, more than doubling year‑over‑year. This growth underscores the market’s appetite for AI‑augmented discovery tools. The recent collaboration with Eli Lilly, embedding the TuneLab AI platform into Schrödinger’s LiveDesign cloud suite, further expands the company’s AI portfolio and offers customers a seamless, end‑to‑end solution for hypothesis generation and virtual screening.

Looking ahead, Schrödinger’s AI‑centric roadmap could sharpen its competitive edge against rivals such as Benchling and Certara, especially as pharmaceutical companies intensify AI adoption to reduce R&D costs. Investors should monitor the pace of hosted‑contract adoption, the depth of AI integration with Anthropic, and the incremental revenue contribution from the Lilly partnership. Successful execution could translate into higher gross margins, stronger cash flow, and a more defensible market position in the rapidly evolving biotech software landscape.